Akari Therapeutics to Participate in A.G.P.’s Virtual Healthcare Conference
16 mai 2023 08h00 HE
|
Akari Therapeutics Plc
NEW YORK and LONDON, May 16, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory...
Akari Therapeutics Reports Full-Year 2022 Financial Results and Highlights
01 mai 2023 08h00 HE
|
Akari Therapeutics Plc
Development of lead asset nomacopan, a novel dual-mechanism inhibitor of complement C5 and leukotriene B4 (LTB4), is focused on two priority pipeline programs with potential to transform the...
Akari Therapeutics Granted 180-Day Extension by Nasdaq to Meet Minimum Bid Price Requirement
25 avr. 2023 16h15 HE
|
Akari Therapeutics Plc
NEW YORK and LONDON, April 25, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory...
Akari Therapeutics to Host Key Opinion Leader Webinar on Geographic Atrophy and the Potential of Long-Acting PAS-Nomacopan to Address Significant Unmet Needs
14 avr. 2023 08h00 HE
|
Akari Therapeutics Plc
Event on May 22nd will feature Elias Reichel, M.D., Professor, Department of Ophthalmology, Tufts University School of Medicine NEW YORK and LONDON, April 14, 2023 (GLOBE NEWSWIRE) -- Akari...
Akari Therapeutics to Attend ARVO 2023, the Annual Meeting of The Association for Research in Vision and Ophthalmology
11 avr. 2023 08h00 HE
|
Akari Therapeutics Plc
NEW YORK and LONDON, April 11, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory...
Akari Therapeutics Announces a Case Study from the Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA Will Be Presented at The European Society for Blood and Marrow Transplantation (EBMT) 49th Annual Meeting
03 avr. 2023 08h00 HE
|
Akari Therapeutics Plc
NEW YORK and LONDON, April 03, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory...
Akari Therapeutics, Plc Announces $4 Million Registered Direct Offering
30 mars 2023 09h09 HE
|
Akari Therapeutics Plc
Offering includes 100% participation by Akari’s Board of Directors, including Akari President and CEO Rachelle JacquesOffering includes accredited investors who have not previously...
Poland and U.K. Regulatory Authorities – URPL and MHRA – Approve Use of New, Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Study
29 mars 2023 08h00 HE
|
Akari Therapeutics Plc
Third generation drug substance manufacturing process increases the final yield of nomacopan by at least 5-fold, improving cost efficiencies in the continuing Phase 3 clinical trial of nomacopan in...
Akari Therapeutics Announces Presentation of a Case Study from Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA as a Late-Breaker at The Transplantation & Cellular Therapy Tandem Meetings
21 févr. 2023 08h00 HE
|
Akari Therapeutics Plc
NEW YORK and LONDON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory...
Akari Therapeutics Announces Pre-Clinical Development Progress Toward Potential IND on Long-Acting PAS-Nomacopan for Geographic Atrophy (GA)
15 févr. 2023 08h00 HE
|
Akari Therapeutics Plc
Akari is targeting an Investigational New Drug (IND) application submission to the U.S. Food and Drug Administration in the first half of 2024Composition of matter patent application filed on...